Gilead Sciences, Inc. logo
Gilead Sciences, Inc. (GILD)
Compare

Gilead Sciences, Inc. (GILD) EV/Sales Ratio: 5.80x

popular:market cap|pe ratio|revenue|price history|total return

Is Gilead Sciences, Inc.’s EV/Sales ratio high or low?

Gilead Sciences, Inc.'s EV/Sales ratio of 5.80x is 25% above its 5-year average of 4.64x, around the middle of its 5-year range (3.45x–7.32x).

As of Friday, June 12, 2026. 3.68% below its 12-month average of 6.02x.

EV/EBITDA|P/S Ratio|Revenue|All Metrics

GILD EV/Sales Ratio Chart

GILD EV/Sales Ratio
5.80x+7.81% 1Y
Zoom

GILD Average EV/Sales Ratio Chart

GILD Current vs Average EV/Sales Ratio Chart

GILD EV/Sales Ratio Metrics

EV/SALES RATIO

5.80x

EV/SALES RATIO AVG TTM

6.02x

EV/SALES RATIO AVG 3Y

4.98x

EV/SALES RATIO AVG 5Y

4.64x

EV/SALES RATIO AVG 10Y

4.47x

EV/SALES RATIO AVG 15Y

5.44x

EV/SALES RATIO AVG 20Y

6.25x

CURRENT VS TTM AVG

-3.68%

CURRENT VS 3Y AVG

+16.38%

CURRENT VS 5Y AVG

+25.03%

CURRENT VS 10Y AVG

+29.84%

CURRENT VS 15Y AVG

+6.66%

CURRENT VS 20Y AVG

-7.19%

GILD Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Gilead Sciences, Inc. (GILD)$156.28B5.80x6.02x4.98x4.64x
Abbott Laboratories (ABT)$156.15B4.07x4.94x5.00x4.98x
Pfizer Inc. (PFE)$149.18B3.36x3.30x3.43x3.63x
Intuitive Surgical, Inc. (ISRG)$146.23B13.85x18.40x19.52x18.69x
Thermo Fisher Scientific Inc. (TMO)$176.77B4.81x5.13x5.38x5.61x
CVS Health Corporation (CVS)$129.25B0.48x0.44x0.43x0.51x
Danaher Corporation (DHR)$128.27B5.71x6.62x7.16x7.00x
Amgen Inc. (AMGN)$191.09B6.39x6.19x6.53x6.38x
Bristol-Myers Squibb Company (BMY)$116.19B3.12x2.99x3.12x3.47x
Vertex Pharmaceuticals Incorporated (VRTX)$112.95B9.02x9.43x10.00x9.07x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Gilead Sciences, Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Gilead Sciences, Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The EV/Sales ratio for GILD stock is 5.80x.
Is Gilead Sciences, Inc.'s EV/Sales ratio high or low?
Gilead Sciences, Inc.'s EV/Sales ratio of 5.80x is 25% above its 5-year average of 4.64x, around the middle of its 5-year range (3.45x–7.32x).
What is the TTM average EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The TTM average EV/Sales ratio for GILD stock is 6.02x.
What is the 3Y average EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The 3Y average EV/Sales ratio for GILD stock is 4.98x.
What is the 5Y average EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The 5Y average EV/Sales ratio for GILD stock is 4.64x.
What is the 10Y average EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The 10Y average EV/Sales ratio for GILD stock is 4.47x.
What is the 15Y average EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The 15Y average EV/Sales ratio for GILD stock is 5.44x.
What is the 20Y average EV/Sales ratio for Gilead Sciences, Inc. (GILD)?
The 20Y average EV/Sales ratio for GILD stock is 6.25x.

Gilead Sciences, Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-115.80x
2026-06-105.61x
2026-06-095.78x
2026-06-085.89x
2026-06-055.94x
2026-06-045.94x
2026-06-035.93x
2026-06-025.87x
2026-06-016.02x
2026-05-296.16x
2026-05-286.23x
2026-05-276.13x
2026-05-266.13x
2026-05-226.16x
2026-05-215.99x
2026-05-206.00x
2026-05-195.99x
2026-05-185.96x
2026-05-155.95x
2026-05-146.06x
2026-05-136.10x
2026-05-126.18x
2026-05-116.12x
2026-05-086.03x
2026-05-076.14x
2026-05-066.38x
2026-05-056.26x
2026-05-046.23x
2026-05-016.18x
2026-04-306.15x
2026-04-296.06x
2026-04-286.08x
2026-04-276.02x
2026-04-246.13x
2026-04-236.27x
2026-04-226.23x
2026-04-216.25x
2026-04-206.36x
2026-04-176.44x
2026-04-166.48x
2026-04-156.53x
2026-04-146.56x
2026-04-136.50x
2026-04-106.49x
2026-04-096.63x
2026-04-086.60x
2026-04-076.49x
2026-04-066.54x
2026-04-026.52x
2026-04-016.55x
2026-03-316.51x
2026-03-306.38x
2026-03-276.29x
2026-03-266.40x
2026-03-256.46x
2026-03-246.46x
2026-03-236.42x
2026-03-206.42x
2026-03-196.58x
2026-03-186.59x
2026-03-176.72x
2026-03-166.76x
2026-03-136.75x
2026-03-126.76x
2026-03-116.79x
2026-03-106.90x
2026-03-096.82x
2026-03-066.70x
2026-03-056.76x
2026-03-046.89x
2026-03-036.87x
2026-03-026.96x
2026-02-276.92x
2026-02-266.70x
2026-02-256.84x
2026-02-246.86x
2026-02-237.07x
2026-02-207.13x
2026-02-197.12x
2026-02-187.19x
2026-02-177.30x
2026-02-137.29x
2026-02-127.15x
2026-02-117.32x
2026-02-106.95x
2026-02-097.14x
2026-02-067.18x
2026-02-057.05x
2026-02-046.91x
2026-02-036.78x
2026-02-026.77x
2026-01-306.73x
2026-01-296.62x
2026-01-286.63x
2026-01-276.68x
2026-01-266.55x
2026-01-236.47x
2026-01-226.26x
2026-01-216.17x
2026-01-205.96x
2026-01-165.99x
2026-01-155.83x
2026-01-145.95x
2026-01-135.85x
2026-01-125.89x
2026-01-095.83x
2026-01-085.81x
2026-01-075.97x
2026-01-065.84x
2026-01-055.71x
2026-01-025.85x
2025-12-315.90x
2025-12-305.92x
2025-12-295.99x
2025-12-265.98x
2025-12-246.02x
2025-12-236.00x
2025-12-225.96x
2025-12-195.96x
2025-12-185.84x
2025-12-175.84x
2025-12-165.73x
2025-12-155.77x
2025-12-125.80x
2025-12-115.92x
2025-12-105.84x
2025-12-095.75x
2025-12-085.83x
2025-12-055.83x
2025-12-045.89x
2025-12-035.99x
2025-12-025.95x
2025-12-015.97x
2025-11-286.03x
2025-11-266.10x
2025-11-256.09x
2025-11-246.01x
2025-11-216.07x
2025-11-205.99x
2025-11-196.13x
2025-11-186.09x
2025-11-175.96x
2025-11-146.00x
2025-11-136.00x
2025-11-125.93x
2025-11-115.89x
2025-11-105.70x
2025-11-075.73x
2025-11-066.05x
2025-11-056.02x
2025-11-046.03x
2025-11-035.99x
2025-10-315.89x
2025-10-305.84x
2025-10-295.84x
2025-10-285.81x
2025-10-275.92x
2025-10-245.94x
2025-10-235.94x
2025-10-225.97x
2025-10-216.08x
2025-10-206.04x
2025-10-176.03x
2025-10-165.81x
2025-10-155.83x
2025-10-145.84x
2025-10-135.83x
2025-10-105.78x
2025-10-095.76x
2025-10-085.83x
2025-10-075.76x
2025-10-065.62x
2025-10-035.59x
2025-10-025.49x
2025-10-015.52x
2025-09-305.51x
2025-09-295.58x
2025-09-265.56x
2025-09-255.51x
2025-09-245.63x
2025-09-235.66x
2025-09-225.58x
2025-09-195.65x
2025-09-185.63x
2025-09-175.57x
2025-09-165.51x
2025-09-155.58x
2025-09-125.67x
2025-09-115.81x
2025-09-105.70x
2025-09-095.72x
2025-09-085.72x
2025-09-055.69x
2025-09-045.59x
2025-09-035.60x
2025-09-025.59x
2025-08-295.60x
2025-08-285.58x
2025-08-275.64x
2025-08-265.68x
2025-08-255.65x
2025-08-225.68x
2025-08-215.74x
2025-08-205.85x
2025-08-195.82x
2025-08-185.82x
2025-08-155.83x
2025-08-145.86x
2025-08-135.91x
2025-08-125.90x
2025-08-115.92x
2025-08-085.88x
2025-08-075.48x
2025-08-065.42x
2025-08-055.52x
2025-08-045.61x
2025-08-015.55x
2025-07-315.51x
2025-07-305.62x
2025-07-295.60x
2025-07-285.55x
2025-07-255.68x
2025-07-245.55x
2025-07-235.57x
2025-07-225.42x
2025-07-215.34x
2025-07-185.33x
2025-07-175.36x
2025-07-165.41x
2025-07-155.37x
2025-07-145.50x
2025-07-115.40x
2025-07-105.61x
2025-07-095.55x
2025-07-085.46x
2025-07-075.49x
2025-07-035.49x
2025-07-025.48x
2025-07-015.49x
2025-06-305.45x
2025-06-275.44x
2025-06-265.31x
2025-06-255.23x
2025-06-245.29x
2025-06-235.25x
2025-06-205.35x
2025-06-185.32x
2025-06-175.32x
2025-06-165.45x
2025-06-135.41x
2025-06-125.50x
2025-06-115.38x
2025-06-105.42x
2025-06-095.54x
2025-06-065.52x
2025-06-055.43x
2025-06-045.37x
2025-06-035.38x
2025-06-025.36x
2025-05-305.42x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA
17,600 employees
www.gilead.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
View full financials